Treatment of Influenza A with Prolonged Fever

Antiviral Treatment

The Infectious Diseases Society of America recommends oseltamivir (Tamiflu) as the preferred first-line treatment for influenza A, even when symptoms have been present for more than 48 hours, particularly in patients with severe or persistent symptoms 1
Standard adult dosing of oseltamivir is 75 mg twice daily for 5 days; pediatric dosing is weight-based (≤15 kg: 30 mg twice daily; >15-23 kg: 45 mg twice daily; >23-40 kg: 60 mg twice daily; >40 kg: 75 mg twice daily) 2
For patients with persistent fever after 6 days, a longer duration of antiviral treatment may be considered, especially if there is evidence of ongoing viral replication 1, 3
The American College of Physicians suggests that clinicians should consider longer treatment for patients with severe disease, particularly those with respiratory complications 1

The Centers for Disease Control and Prevention recommends that persistent fever beyond 3-5 days strongly suggests a complication such as bacterial coinfection, which requires investigation and empiric treatment 1
Clinicians should investigate and empirically treat bacterial coinfection in patients with influenza who have persistent fever, extensive pneumonia, respiratory failure, or hypotension 1
Diagnostic testing should include respiratory specimens for bacterial culture, blood cultures, and chest imaging 4

The World Health Organization recommends symptomatic treatment of fever, including paracetamol (acetaminophen) or ibuprofen (with caution) 5
Antipyretics should not be used solely to reduce body temperature but rather to alleviate distressing symptoms 5
Adequate hydration (drinking plenty of fluids, but no more than 2 liters per day) is recommended 5

The Infectious Diseases Society of America suggests that for patients with persistent fever despite appropriate antiviral therapy, consider the possibility of antiviral resistance 1, 3
Influenza NAI resistance testing should be considered for patients with evidence of persistent influenza viral replication (e.g., after 7-10 days) who remain ill during or after NAI treatment 1
In immunocompromised patients, viral shedding may be prolonged, and longer courses of antiviral therapy may be necessary 3

Some experts recommend doubling the dose of oseltamivir (150 mg twice daily in adults) for critically ill patients with persistent symptoms, although evidence for this approach is limited 3
Intravenous antiviral therapy (peramivir) may be considered in severely ill patients who have progressed despite oral therapy or when there are concerns about oral absorption 3
For patients with renal impairment (CrCl <30 mL/min), the dose of oseltamivir should be reduced to 75 mg once daily 3

Patients should be advised to seek immediate medical attention if they develop shortness of breath, painful or difficult breathing, bloody sputum, drowsiness, disorientation, or confusion 5
Close monitoring is essential for patients with persistent fever to detect deterioration or complications early 4

The Centers for Disease Control and Prevention recommends that patients should be advised on infection control measures to prevent transmission, including hand hygiene and respiratory etiquette 4
Household contacts may benefit from post-exposure prophylaxis with oseltamivir if they are at high risk for complications 4